At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control Study
É. Sbidian(Inserm), S. Barbarot(Hotel Dieu Hospital), S. Ferkal(Lyon 1 Université), L. Valeyrie‐Allanore, P. Combemale(Centre Léon Bérard), Sylvie Bastuji‐Garin(Inserm), Pierre Brugière(Assistance Publique – Hôpitaux de Paris), Cédric Vialette(Assistance Publique – Hôpitaux de Paris), J.‐P. Lefaucheur(Université Paris-Est Créteil), P. Wolkenstein(Université Paris-Est Créteil), A. Drouet(Hôpital d'instruction des Armées Desgenettes)
Cited by 23
Related Papers
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419
European guideline (<scp>EuroGuiDerm</scp>) on atopic eczema – part <scp>II</scp>: non‐systemic treatments and treatment recommendations for special <scp>AE</scp> patient populations
|Journal of the European Academy of Dermatology and Venereology|2022|271
Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1
|American Journal of Medical Genetics|2000|241